What diseases does Seladelpar’s indications mainly include?

Seladelpar is a selective peroxisome proliferator-activated receptor delta (PPARdelta) agonist, mainly used to treat metabolic and immune-related diseases. It regulates lipid metabolism and inflammatory response by activating PPAR delta receptors, thereby improving disease symptoms and preventing disease progression. In recent years, Siladepa has shown broad application potential in clinical research, especially in the field of liver and metabolic diseases.

First of all, Siladepa is mainly suitable for primary biliary cholangitis (PBC). PBC is an autoimmune liver disease that causes gradual damage to bile ducts, cholestasis, and liver inflammation and fibrosis. Traditional treatment options include drugs such as ursodeoxycholic acid, but some patients do not respond well to them. Siladepa regulates liver lipid metabolism and has anti-inflammatory effects, improves bile flow and reduces liver damage, making it a potential new treatment for PBC patients.

Secondly, Siladepa has also attracted much attention in the treatment of non-alcoholic steatohepatitis (NASH). NASH is a severe manifestation of non-alcoholic fatty liver disease (NAFLD), which is often accompanied by liver inflammation and fibrosis. If not treated in time, it can develop into cirrhosis or even liver cancer. Siladepa regulates lipid metabolism, reduces hepatic fat accumulation, and exerts anti-inflammatory and anti-fibrotic effects, which helps alleviate the pathological changes of NASH and improve liver function.

In addition, Siladepa may also play a role in other metabolic syndrome-related diseases, such as hyperlipidemia and diabetes. By activatingPPARδ, Siladepa promotes fatty acid oxidation and energy metabolism, helping to improve blood lipid levels and insulin sensitivity. As more clinical trials are conducted, the scope of indications for Siladepa is expected to be further expanded and it will become one of the important drugs for the treatment of various metabolic and immune-related diseases.

Reference materials:https://www.drugs.com/donanemab.html